These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23473447)

  • 1. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.
    Cardoos A; Inamori A; Sanacora G; Fava M; Mischoulon D
    Psychosomatics; 2013; 54(5):488-92. PubMed ID: 23473447
    [No Abstract]   [Full Text] [Related]  

  • 2. Visual hallucinations from the addition of riluzole to memantine and bupropion.
    Pittenger C; Naungayan C; Kendell SF; Coric V; Malison R; Krystal JH; Sanacora GS
    J Clin Psychopharmacol; 2006 Apr; 26(2):218-20. PubMed ID: 16633160
    [No Abstract]   [Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
    Wilkinson ST; Kiselycznyk C; Banasr M; Webler RD; Haile C; Mathew SJ
    J Affect Disord; 2018 Dec; 241():514-518. PubMed ID: 30153634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    J Psychiatr Res; 2014 Nov; 58():197-9. PubMed ID: 25139008
    [No Abstract]   [Full Text] [Related]  

  • 8. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 9. A word to the wise about ketamine.
    Schatzberg AF
    Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
    [No Abstract]   [Full Text] [Related]  

  • 10. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ
    Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract]   [Full Text] [Related]  

  • 11. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
    Kellner CH; Greenberg RM; Ahle GM; Liebman LS
    Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
    [No Abstract]   [Full Text] [Related]  

  • 12. Riluzole augmentation for treatment-resistant depression.
    Sanacora G; Kendell SF; Fenton L; Coric V; Krystal JH
    Am J Psychiatry; 2004 Nov; 161(11):2132. PubMed ID: 15514421
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment-Resistant Depression and Ketamine Response in a Patient With Bilateral Amygdala Damage.
    Scheele D; Zimbal S; Feinstein JS; Delis A; Neumann C; Mielacher C; Philipsen A; Hurlemann R
    Am J Psychiatry; 2019 Dec; 176(12):982-986. PubMed ID: 31787017
    [No Abstract]   [Full Text] [Related]  

  • 15. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hepatitis after riluzole administration.
    Remy AJ; Camu W; Ramos J; Blanc P; Larrey D
    J Hepatol; 1999 Mar; 30(3):527-30. PubMed ID: 10190739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderately severe acute pancreatitis associated with riluzole.
    Ianiro G; Cammarota G; Milani A; Mettimano M; Gasbarrini A
    J Clin Gastroenterol; 2014 Jul; 48(6):563. PubMed ID: 24356456
    [No Abstract]   [Full Text] [Related]  

  • 20. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
    Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
    Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.